Crotalus simus venom (CsV)

Crotalus simus venom is a complex biological mixture produced by the Middle American Rattlesnake, consisting of a diverse array of proteins and peptides with potent physiological activities [1]. The venom's composition is characterized by significant geographic variation, often categorized into Type I (high neurotoxicity due to crotoxin) and Type II (high hemorrhagic activity due to metalloproteinases) [2][4]. Key molecular components include phospholipases A2, snake venom metalloproteinases (SVMPs), and serine proteases, which collectively disrupt the nervous system, blood coagulation cascade, and tissue integrity [1][3]. In clinical medicine, this venom is the primary target for polyvalent antivenoms, which employ purified immunoglobulin fragments to sequester and neutralize toxins before they reach their physiological targets [5]. Beyond its role in envenomation, the venom serves as a rich source of bioactive molecules for drug discovery, particularly in the development of anticoagulants and analgesics [6]. However, the complexity and variability of the venom pose significant challenges for standardized treatment and the management of hypersensitivity reactions to antivenom therapies [3][5].

Other names

Middle American Rattlesnake venomCentral American Rattlesnake venomCrotalus durissus simus venom

Neutralization of venom components through antibody-mediated sequestration (antivenom) or small molecule inhibition of specific enzymatic toxins such as phospholipase A2 (varespladib).